Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062368 | 0.88 | PRMT5 (0.45) | CHRNB2CCNA2CDK2AURKATBK1 | |
| SCHEMBL4051426 | 0.86 | AURKA (0.42) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL13608335 | 0.85 | CHRNB1 (0.42) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL4060141 | 0.83 | LMNA (0.46) | CCNA2CDK2AURKAPRMT5IGF1R | |
| SCHEMBL4054953 | 0.83 | FGFR1 (0.49) | AURKATBK1IKBKE | |
| SCHEMBL4054205 | 0.82 | SCD (0.44) | CCNA2CDK2AURKAPRMT5IGF1R | |
| SCHEMBL4060694 | 0.81 | AURKA (0.45) | AURKATBK1IKBKE | |
| SCHEMBL4055195 | 0.81 | AURKA (0.60) | CDK2AURKATBK1IKBKE | |
| SCHEMBL4239405 | 0.81 | GABRA1 (0.43) | CDK2AURKATBK1IKBKEPRMT5 | |
| SCHEMBL4055260 | 0.81 | AURKA (0.47) | CDK2AURKATBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | CHRNB1 1679/4885CHRNB2 2923/4885CHRNB4 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.